Cycurion Reports First Quarter 2026 Results
| Quarterly Results of Operations and Non-GAAP Financial Measures (Unaudited) | |||||||||||
| Quarterly Consolidated Results of Operations | |||||||||||
| For the Three Months Ended | |||||||||||
| March 31, 2026 | December 31, 2025 | March 31, 2025 | |||||||||
| Revenue | $ | 3,268,620 | $ | 3,542,644 | $ | 3,870,050 | |||||
| Cost of revenue | 2,580,262 | 3,114,505 | 3,192,287 | ||||||||
| Gross profit | 688,358 | 428,139 | 677,763 | ||||||||
| Gross margin | 21.1 | % | 12.1 | % | 17.5 | % | |||||
| Operating expenses: | |||||||||||
| Selling, general and administrative expenses | 2,743,695 | 4,013,876 | 337,374 | ||||||||
| Stock compensation expenses | 315,833 | 804,424 | - | ||||||||
| Business combination expenses | - | 630,000 | 10,437,894 | ||||||||
| Total operating expenses | 3,059,528 | 5,448,300 | 10,775,268 | ||||||||
| Operating loss | (2,371,170 | ) | (5,020,161 | ) | (10,097,505 | ) | |||||
| Interest income | 14,236 | 25,768 | - | ||||||||
| Interest expense | (204,852 | ) | (257,174 | ) | (178,890 | ) | |||||
| Gain on debt settlement, net | - | (28,504 | ) | 141,653 | |||||||
| Other expense | - | - | (113,744 | ) | |||||||
| Other expense, net | (190,616 | ) | (259,910 | ) | (150,981 | ) | |||||
| Loss before income taxes | (2,561,786 | ) | (5,280,071 | ) | (10,248,486 | ) | |||||
| Provision for income tax | - | - | - | ||||||||
| Net loss | (2,561,786 | ) | (5,280,071 | ) | (10,248,486 | ) | |||||
| Less: Net loss attributable to non-controlling interest | 433,324 | 175,017 | - | ||||||||
| Net loss attributable to Cycurion | $ | (2,128,462 | ) | $ | (5,105,054 | ) | $ | (10,248,486 | ) | ||
| Reconciliation of Net Loss to EBITDA (Non-GAAP) and Adjusted EBITDA (Non-GAAP) | |||||||||||
| For the Three Months Ended | |||||||||||
| March 31, 2026 | December 31, 2025 | March 31, 2025 | |||||||||
| Net loss attributable to Cycurion | $ | (2,128,462 | ) | $ | (5,105,054 | ) | $ | (10,248,486 | ) | ||
| Interest income | (14,236 | ) | (25,768 | ) | - | ||||||
| Interest expense | 204,852 | 257,174 | 178,890 | ||||||||
| Other expense | - | - | 113,744 | ||||||||
| Depreciation and amortization | 1,187 | 7,665 | 74,892 | ||||||||
| EBITDA (Non-GAAP) | (1,936,659 | ) | (4,865,983 | ) | (9,880,960 | ) | |||||
| Loss on debt settlement, net | - | 28,504 | (141,653 | ) | |||||||
| Transaction related expenses | - | 630,000 | 10,437,894 | ||||||||
| Finance expense | - | - | 100,000 | ||||||||
| Stock-based compensation | 315,833 | 904,424 | - | ||||||||
| Adjusted EBITDA (Non-GAAP) | $ | (1,620,826 | ) | $ | (3,303,055 | ) | $ | 515,281 | |||
| CYCURION, INC. AND SUBSIDIARIES CONSOLIDATED BALANCE SHEETS (Unaudited) | |||||||
| March 31, 2026 | December 31, 2025 | ||||||
| Assets: | |||||||
| Cash and cash equivalents | $ | 2,028,718 | $ | 5,255,235 | |||
| Accounts receivable, net | 3,336,047 | 2,687,479 | |||||
| Prepaid expenses and other current assets | 106,934 | 60,133 | |||||
| Total current assets | 5,471,699 | 8,002,847 | |||||
| Software development costs, net | 4,735,981 | 4,606,981 | |||||
| Goodwill | 21,238,450 | 20,842,508 | |||||
| Total non-current assets | 25,974,431 | 25,449,489 | |||||
| Total assets | $ | 31,446,130 | $ | 33,452,336 | |||
| Liabilities and Stockholders' Equity: | |||||||
| Liabilities: | |||||||
| Bank loan-revolving credit line | $ | 2,725,546 | $ | 2,933,396 | |||
| Loans payable - current portion | 669,693 | 669,693 | |||||
| Factoring liability | 1,566,887 | 1,511,678 | |||||
| Convertible notes | 192,897 | 192,897 | |||||
| Promissory notes | 2,500,849 | 2,499,662 | |||||
| Loans payable - related parties | 123,650 | 123,650 | |||||
| Accounts payable | 1,441,596 | 1,314,772 | |||||
| Accrued liabilities | 4,283,045 | 4,228,337 | |||||
| Accrued compensation and benefits | 1,306,906 | 919,825 | |||||
| Accrued interest payable | 1,486,041 | 1,347,787 | |||||
| Excise tax payable | 1,167,173 | 1,167,173 | |||||
| Total current liabilities | 17,464,283 | 16,908,870 | |||||
| Loans payable - non-current portion | 300,000 | 300,000 | |||||
| Total non-current liabilities | 300,000 | 300,000 | |||||
| Total liabilities | 17,764,283 | 17,208,870 | |||||
| Stockholders' Equity: | |||||||
| Preferred stock ($0.0001 par value, 20,000,000 shares authorized) | |||||||
| Series A convertible preferred stock ($0.0001 par value, 110,000 shares designated, 0 and 0 issued and outstanding, respectively) | - | - | |||||
| Series B convertible preferred stock ($0.0001 par value, 3,000 shares designated, 0 and 1 issued and outstanding, respectively) | - | - | |||||
| Series C convertible preferred stock ($0.0001 par value, 5,000 shares designated, 2,547 and 4,851 issued and outstanding, respectively) | - | - | |||||
| Series D convertible preferred stock ($0.0001 par value, 6,666,700 shares designated, 150,000 and 150,000 issued and outstanding, respectively) | 15 | 15 | |||||
| Series E convertible preferred stock ($0.0001 par value, 100 shares designated, 51 and 51 issued and outstanding, respectively) | - | - | |||||
| Series F convertible preferred stock ($0.0001 par value, 10,000 shares designated, 0 and 0 issued and outstanding, respectively) | - | - | |||||
| Series G convertible preferred stock ($0.0001 par value, 10,000 shares designated, 143 and 143 issued and outstanding, respectively) | - | - | |||||
| Common stock ($0.0001 par value, 300,000,000 shares authorized, 5,510,021 and 3,642,501 shares issued and outstanding, respectively) | 551 | 364 | |||||
| Additional paid in capital | 46,979,742 | 46,979,762 | |||||
| Accumulated deficit | (29,007,543 | ) | (26,879,081 | ) | |||
| Total stockholders' equity attributable to Cycurion | 17,972,765 | 20,101,060 | |||||
| Deficit attributable to noncontrolling interests | (4,290,918 | ) | (3,857,594 | ) | |||
| Total stockholders' equity | 13,681,847 | 16,243,466 | |||||
| Total liabilities and stockholders' equity | $ | 31,446,130 | $ | 33,452,336 | |||
| CYCURION, INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited) | |||||||
| For the Three Months Ended March 31, | |||||||
| March 31, 2026 | March 31, 2025 | ||||||
| Revenue | $ | 3,268,620 | $ | 3,870,050 | |||
| Cost of revenue | 2,580,262 | 3,192,287 | |||||
| Gross profit | 688,358 | 677,763 | |||||
| Operating expenses: | |||||||
| Selling, general and administrative expenses | 2,743,695 | 337,374 | |||||
| Stock compensation expenses | 315,833 | - | |||||
| Business combination expenses | - | 10,437,894 | |||||
| Total operating expenses | 3,059,528 | 10,775,268 | |||||
| Operating loss | (2,371,170 | ) | (10,097,505 | ) | |||
| Other income/(expenses): | |||||||
| Interest income | 14,236 | - | |||||
| Interest expense | (204,852 | ) | (178,890 | ) | |||
| Gain on debt settlement, net | - | 141,653 | |||||
| Other expense, net | - | (113,744 | ) | ||||
| Other expenses, net | (190,616 | ) | (150,981 | ) | |||
| Loss before income taxes | (2,561,786 | ) | (10,248,486 | ) | |||
| Provision for income tax | - | - | |||||
| Net loss | (2,561,786 | ) | (10,248,486 | ) | |||
| Less: Net loss attributable to non-controlling interest | 433,324 | - | |||||
| Net loss attributable to Cycurion | $ | (2,128,462 | ) | $ | (10,248,486 | ) | |
| Comprehensive loss | $ | (2,128,462 | ) | $ | (10,248,486 | ) | |
| Loss per share: | |||||||
| Basic | $ | (0.47 | ) | $ | (15.57 | ) | |
| Diluted | $ | (0.47 | ) | $ | (7.40 | ) | |
| Weighted average shares outstanding: | |||||||
| Basic | 4,561,976 | 658,218 | |||||
| Diluted | 4,561,976 | 1,383,507 |
| CYCURION, INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) | |||||||
| For the Three Months Ended March 31, | |||||||
| 2026 | 2025 | ||||||
| Cash flows from operating activities: | |||||||
| Net loss | $ | (2,561,786 | ) | $ | (10,248,486 | ) | |
| Adjustments to reconcile net loss to net cash used in operating activities: | |||||||
| Stock-based compensation | 315,833 | - | |||||
| Stock-based compensation - business combination related | - | 9,250,000 | |||||
| Amortization of debt discount | 1,187 | 64,850 | |||||
| Depreciation of property and equipment | - | 1,709 | |||||
| Amortization of software development costs | - | 8,333 | |||||
| Gain on debt settlement, net | - | (141,653 | ) | ||||
| Finance expense | - | 100,000 | |||||
| Changes in assets and liabilities: | |||||||
| Accounts receivable, net and other receivables | (648,568 | ) | (1,300,686 | ) | |||
| Prepaid expenses and other current assets | (46,801 | ) | (11,415 | ) | |||
| Accounts payable and accrued liabilities | (184,201 | ) | (286,114 | ) | |||
| Accrued compensation and benefits | 96,248 | 37,673 | |||||
| Accrued interest payable | 138,254 | (219,320 | ) | ||||
| Net cash used in operating activities | (2,889,834 | ) | (2,745,109 | ) | |||
| Cash flows from investing activities: | |||||||
| Cash acquired on business combination | - | 34,983 | |||||
| Capitalized software development costs | (129,000 | ) | (70,000 | ) | |||
| Cash withdrawn from Trust Account in connection with redemption | - | 1,001,216 | |||||
| Release of Trust Account to Company's bank account | - | 833,324 | |||||
| Net cash (used in)/provided by investing activities | (129,000 | ) | 1,799,523 | ||||
| Cash flows from financing activities: | |||||||
| Proceeds from exercise of warrants | 167 | 3,309,921 | |||||
| Redemption of common stock subject to redemption | - | (1,001,216 | ) | ||||
| Repayments of revolving line of credit | (207,850 | ) | (9,300 | ) | |||
| Repayment of bank borrowings | - | (5,114 | ) | ||||
| Proceeds from convertible notes payable | - | 386,500 | |||||
| Proceeds from notes payable | - | 513,200 | |||||
| Repayments of notes payable | - | (20,000 | ) | ||||
| Net cash (used in)/provided by financing activities | (207,683 | ) | 3,173,991 | ||||
| Net (decrease)/increase in cash and cash equivalents | (3,226,517 | ) | 2,228,405 | ||||
| Cash and cash equivalents, beginning of period | 5,255,235 | 40,790 | |||||
| Cash and cash equivalents, end of period | $ | 2,028,718 | $ | 2,269,195 |

Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.

Comments
No comment